Google NewsRace Oncology (ASX:RAC): Oncology Stock Commands Huge Market Interest After $34.3m Raising - Kalkine
Race Oncology (ASX:RAC): Oncology Stock Commands Huge Market Interest After $34.3m Raising Kalkine
RACURA ONCOLOGY ORDINARY (RAC) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Clinical-stage biotech Racura Oncology raises $34.3m to fully fund three cancer drug trials
Clinical-stage biotechnology company Racura Oncology (ASX: RAC) has raised a total of $34.3 million over two years to fully fund three clinical trials of its lead oncology asset RC220, completing the capital raise without paying any broker or underwriter fees. The funds, accumulated since June 2024 through a combination of bonus and "piggyb...
ASXRacura Oncology Investor Briefings Perth & Auckland
other announcement
Racura raised $34.3m to Advance Three Oncology Trials
other announcement
Kalkine ASX Spotlight: What Weighed on Race Oncology (ASX:RAC) Shares Today? - Kalkine
Kalkine ASX Spotlight: What Weighed on Race Oncology (ASX:RAC) Shares Today? Kalkine
Racura Oncology (ASX:RAC) Surges 8% as RC220 Trial Cleared to Double Dosage Level - Stocks Down Under
Racura Oncology (ASX:RAC) Surges 8% as RC220 Trial Cleared to Double Dosage Level Stocks Down Under
Small CapsCPACS Trial Cleared to Escalate to Next RC220 Dose Level
other announcement
March 2026 Quarterly Activity Report and Appendix 4C
other announcement
Motley FoolInsurance Australia Group's RAC Insurance deal faces ACCC Phase 2 review
Insurance Australia Group’s bid for RAC Insurance faces ACCC’s Phase 2 review over competition in Western Australia. The post Insurance Australia Group's RAC Insurance deal faces ACCC Phase 2 review appeared first on The Motley Fool Australia.
KalkineIs RACura Oncology Limited (ASX:RAC) Building Strength in All Ordinaries Biotech Sector?
Highlights RACura Oncology progresses quotation of newly issued shares on ASX. Developments align with healthcare and biotechnology sector activity. Australian indices reflect participation from medical research companies. RACura Oncology progresses share quotation, highlighting developments within the healthcare and biotechnology sector across the All Ordinaries index. The healthcare and biotechnology sector represents a vital component of Australia’s economic and innovation land...
StockheadLong Shortz with Racura: Tackling MYC-driven cancer pathways
Racura Oncology advances its HARNESS-1 lung cancer trial, now actively recruiting, with early readouts expected later this year. ... Read More The post Long Shortz with Racura: Tackling MYC-driven cancer pathways appeared first on Stockhead.
First Patient Recruited to HARNESS-1 Lung Cancer Trial
other announcement
Racura and Purdue University Partnership Announced
other announcement
First Patient Dosed Safely with RC220 in Hong Kong
other announcement
Racura Selected to Present at 2026 AACR Annual Meeting
other announcement
Long Shortz with Racura: Lung cancer trial edges closer to patient enrolment
Racura Oncology receives governance approval for its upcoming HARNESS-1 lung cancer trial testing RC220. ... Read More The post Long Shortz with Racura: Lung cancer trial edges closer to patient enrolment appeared first on Stockhead.
Racura HARNESS-1 Trial Receives Governance Approval
other announcement